News - Novartis
Novartis twice-yearly* Leqvio® demonstrated clinically meaningful, statistically significant LDL-C lowering as a monotherapy in patients at low or moderate ASCVD risk. Featured News Aug 22, 2024.
Novartis announces new organizational structure to accelerate …
Apr 4, 2022 · New Operations unit combines Novartis Technical Operations and Customer & Technology Solutions units to generate economies of scale, drive productivity and create a strong technology and operational foundation; G&A functions to be globally integrated
Novartis
Explore the Novartis in Society Integrated Report. Updates and resources for investors including financial information, disclosures, events, share price, ESG and reporting. Information for journalists including media releases, statements, stories, multimedia resources and more. Novartis is hiring!
Novartis bolsters innovative medicines strategy and renal pipeline …
Jun 12, 2023 · Novartis bolsters innovative medicines strategy and renal pipeline with agreement to acquire Chinook Therapeutics for USD 3.2bn upfront (USD 40 / share) Jun 12, 2023. Ad hoc announcement pursuant to Art. 53 LR. Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA ...
Novartis unveils new focused strategy, underpinned by eight …
Sep 22, 2022 · Focus on US and other priority geographies including China, Germany, Japan. These eight brands are underpinning growth across all key geographies, supporting Novartis aspiration to improve competitive positioning and organically build its US business to become a top-five player in the US by 2027.
News Archive - Novartis
Review recent and past Novartis healthcare news stories, including media releases and featured information.
Novartis executes Sandoz Spin-off, completing strategic …
Oct 4, 2023 · Novartis executes separation of the Sandoz business to create an independent company by way of a 100% Spin-off; Shares of Sandoz will be listed and commence trading today on the SIX Swiss Exchange; Spin-off allows shareholders to benefit from a Novartis with capital and management attention fully focused on innovative medicines
Novartis upgrades mid-term sales growth guidance, showcases its ...
Nov 28, 2023 · Mid-term sales guidance upgrade to 5% CAGR (2022-27), with core operating income margin of ~40%+ by 2027, driven by continued strong momentum of key growth drivers. Confidence to grow mid-single digit longer-term based on the foundational strength of de-risked existing brands and pipeline assets. Focused strategy and financial discipline has ...
Our next era - Novartis
Dec 4, 2023 · Novartis poised to expand impact on human health as it begins next era. Dec 04, 2023. It’s a historic moment for Novartis. Following the Sandoz spin-off in October and capping a multi-year transformation, we’ve entered our next era as an innovative medicines company.
FDA approves Novartis Kisqali® to reduce risk of recurrence in …
Basel, September 17, 2024 – Novartis today announced that the US Food and Drug Administration (FDA) has approved Kisqali ® (ribociclib) in combination with an aromatase inhibitor (AI) for the adjuvant treatment of people with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) stage II and III early breast ...